← All trials
NCT04344158
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 1, 2020
- Primary completion
- Jun 30, 2024
- Completion date
- Dec 31, 2024
- First posted
- Apr 14, 2020
- Last posted
- Apr 15, 2020
- Enrollment
- 648
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Jiangsu Chia-tai Tianqing Pharmaceutical Co.,LtdLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.